Vanguard Rapid Resp 3, a vaccine targeting three canine infectious respiratory diseases, has earned a one-year duration of immunity claim from the U.S. Department of Agriculture.
Vaccine maker Zoetis Inc. reported Dec. 18 that the product “is the first and only intranasal vaccine line in the United States” to offer 12 months’ protection against Bordetella bronchiseptica (Bb), canine adenovirus type 2 (CAV-2) and canine parainfluenza virus (CPiV).
“This extended DOI is essential in reducing morbidity and mortality from infectious respiratory disease among dogs in social or commingled environments such as boarding facilities and shelters,” said Zoetis consultant Stephan Carey, DVM, Ph.D., DACVIM, an assistant professor at the Michigan State University College of Veterinary Medicine.
Vanguard Rapid Resp 3 is available in three antigenic options: Bb, CPiV and CAV-2; Bb and CPiV; and Bb only. They may be administered to healthy dogs at least 8 weeks old.
The original Vanguard Rapid Resp was introduced in 2016 with a one-year DOI for Bb and six months for the other antigens.
Zoetis is based in Parsippany, New Jersey.